IMMUNOVANT INC (IMVT)
NASDAQ • Healthcare
$44.3
+$0.58 (+1.3%)
Market open
Last close at August 18, 2026 at 20:00 UTC
Fundamentals Charts
About IMMUNOVANT INC
Immunovant, Inc. is a NASDAQ-listed biotechnology company in the healthcare sector that develops antibody therapies for autoimmune disease. In qualitative terms, it is a clinical-stage business rather than a commercial drug company. The company came public in 2019 and is based in New York City, New York.
Fundamentals & Financials
Revenue (TTM)
$7M
Net Income (TTM)
-$538.2M
EPS (TTM)
-$2.82
ROA (TTM)
-63.13%
Current Ratio
7.27
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Stay Ahead of the Market
Get premium market insights delivered directly to your inbox.
Quote Summary
Previous CloseDay Range$44.3$42.64 - $44.38
52 Week RangeAvg. Volume$14.47 - $44.381M
Market Cap$9.1B
Peers & Related Assets
PRAXPRAXIS PRECISION MEDICINES INC
$369.84-1.7%
KYMRKYMERA THERAPEUTICS INC
$121.38-0.0%
CRNXCRINETICS PHARMACEUTICALS INC
$84.72-0.0%
ACADACADIA PHARMACEUTICALS INC
$30.18+4.0%
DYNDYNE THERAPEUTICS INC
$26-0.6%
VKTXVIKING THERAPEUTICS INC
$33.37-0.8%
RAREULTRAGENYX PHARMACEUTICAL INC
$25.49-2.5%
AKROAkero Therapeutics, Inc.
NAMSNewAmsterdam Pharma Company N.V.
SLNOSOLENO THERAPEUTICS INC